VYNE Therapeutics (VYNE) Stock Forecast & Price Target $0.68 +0.00 (+0.55%) As of 03:15 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Analyst Forecasts Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock VYNE Therapeutics - Analysts' Recommendations and Stock Price Forecast (2026) How MarketBeat Calculates Price Target and Consensus Rating Consensus Rating ReduceBased on 4 Analyst RatingsSell1Hold3Buy0 Based on 4 Wall Street analysts who have issued ratings for VYNE Therapeutics in the last 12 months, the stock has a consensus rating of "Reduce." Out of the 4 analysts, 1 has given a sell rating, and 3 have given a hold rating for VYNE. Consensus Price Target N/A MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data. Get the Latest News and Ratings for VYNE and Related Stocks Enter your email address to receive the latest news and analysts' ratings for VYNE Therapeutics and its competitors. Sign Up View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. VYNE Analyst Ratings Over TimeTypeCurrent Forecast5/19/25 to 5/19/261 Month Ago4/19/25 to 4/19/263 Months Ago2/18/25 to 2/18/261 Year Ago5/19/24 to 5/19/25Strong Buy0 Strong Buy rating(s)0 Strong Buy rating(s)0 Strong Buy rating(s)0 Strong Buy rating(s)Buy0 Buy rating(s)0 Buy rating(s)0 Buy rating(s)2 Buy rating(s)Hold3 Hold rating(s)3 Hold rating(s)3 Hold rating(s)0 Hold rating(s)Sell1 Sell rating(s)1 Sell rating(s)1 Sell rating(s)0 Sell rating(s)Consensus Price TargetN/A$4.50$4.50$6.25Forecasted UpsideN/A637.58% Upside645.03% Upside412.30% UpsideConsensus RatingReduceReduceReduceBuy VYNE Analyst Recommendations By MonthAnalyst Ratings Chart DescriptionThe chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.Skip Chart & View Analyst Rating History VYNE Price Targets by MonthAverage Share Price and Price Target by Month Chart DescriptionThe chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table VYNE Therapeutics Stock vs. The CompetitionTypeVYNE TherapeuticsMedical CompaniesBroader MarketConsensus Rating Score 1.75 2.30 2.52Consensus RatingReduceHoldModerate BuyPredicted UpsideN/A1,693.83% Upside17.04% UpsideNews Sentiment RatingVery Positive NewsSee Recent VYNE NewsPositive NewsPositive News Recent Analyst Forecasts and Stock Ratings All Ratings Strong Buy Buy Hold Sell Rating Show All Upside > 100% Upside 50% - 100% Upside 20% - 50% Upside 10% - 20% Upside 0% - 10% Downside 0% - 10% Downside 10% - 20% Downside 20% - 50% Downside 50% - 100% Downside > 100% Upside/Downside All Actions Upgrades Downgrades Initiates Coverage Raises Target Lowers Target Reiterates Rating Action Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Years 5 Years Time Frame Start Date End Date Most Recent from Each Brokerage All Show Export DateBrokerageAnalystActionRatingPrice TargetReport Date Upside/DownsideDetails5/4/2026 Weiss RatingsNot Rated Reiterated RatingSell (D-)7/31/2025 BTIG Research2 of 5 stars DowngradeBuy ➝ Neutral7/30/2025 Lifesci Capital4 of 5 stars DowngradeStrong-Buy ➝ Hold7/30/2025 HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingJoseph PantginisSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingDowngradeBuy ➝ NeutralAnalyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 03:17 PM ET. VYNE Forecast - Frequently Asked Questions Should I buy or sell VYNE Therapeutics stock right now? 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for VYNE Therapeutics in the last year. There is currently 1 sell rating and 3 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "reduce" VYNE shares. Does VYNE Therapeutics's stock price have much downside? According to analysts, VYNE Therapeutics's stock has a predicted downside of -100.00% based on their 12-month stock forecasts. What analysts cover VYNE Therapeutics? VYNE Therapeutics has been rated by research analysts at Weiss Ratings in the past 90 days. Do Wall Street analysts like VYNE Therapeutics more than its competitors? Analysts like VYNE Therapeutics less than other "medical" companies. The consensus rating for VYNE Therapeutics is Reduce while the average consensus rating for "medical" companies is Hold. Learn more on how VYNE compares to other companies. Stock Forecasts and Research Tools Related Companies Q32 Bio Stock Forecast biote Stock Forecast Flag Ship Acquisition Stock Forecast eXoZymes Stock Forecast Annovis Bio Stock Forecast Acrivon Therapeutics Stock Forecast Citius Oncology Stock Forecast Gossamer Bio Stock Forecast Gain Therapeutics Stock Forecast Spruce Biosciences Stock Forecast Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Brokerages With VYNE Therapeutics RecommendationsWeiss RatingsWall Street ZenBTIG ResearchLifesci CapitalHC Wainwright This page (NASDAQ:VYNE) was last updated on 5/19/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredWhy this tiny stock may move before the SpaceX IPO dropsThe projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...Behind the Markets | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding VYNE Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share VYNE Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
